知镜 Cognispect · 医学文献与研究工作台

Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.

Tallman JE, Hyman MJ, Agarwal PK, Faris SF, Modi PK.
Urology · 2026-10-09 · PMID 42854855

文献摘要

Objective To characterize the utilization of oral pharmacotherapy and minimally invasive non-pharmacologic treatments approved for overactive bladder among patients receiving intravesical therapy for non-muscle invasive bladder cancer, as this treatment is frequently complicated by lower urinary tract symptoms, which are associated with treatment discontinuation and worse oncological outcomes. Methods We conducted a retrospective cohort study using the Merative™ MarketScan® Commercial Database (2016-2024). We identified patients with bladder cancer receiving intravesical bacillus Calmette-Guérin or chemotherapy. The primary outcome was the receipt of lower urinary tract symptom therapy-oral pharmacotherapy (anticholinergics, β-3 agonists, alpha blockers) or minimally invasive non-pharmacologic treatments (botulinum toxin injection, sacral neuromodulation, percutaneous tibial nerve stimulation)-in the 180 days after initiating induction therapy. Results Among 2978 patients, 29.6% received lower urinary tract symptom therapy. Use of alpha blockers (19.9%) and anticholinergics (13.7%) predominated. Use of β-3 agonists (1.3%) or non-pharmacologic treatments was exceedingly rare: only 0.3% received botulinum toxin injection, and no patients received sacral neuromodulation or percutaneous tibial nerve stimulation. Lower urinary tract symptom therapy was associated with a lower proportion of patients completing induction therapy (75.9% vs. 79.0%) (P=0.049) and higher proportion of patients undergoing cystectomy (14.8% vs. 11.9%) (P=0.021). Conclusion While nearly one-third of bladder cancer patients require pharmacotherapy for lower urinary tract symptoms during intravesical treatment, β-3 agonists and non-pharmacologic treatments are almost entirely unutilized. Given the association between lower urinary tract symptoms and induction therapy non-completion, further research into these advanced therapies is warranted to improve patient adherence and oncologic outcomes.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。